| part | subject | predicate | object | published by | date | |
|---|---|---|---|---|---|---|
|
Assertion
|
|
|||||
|
Assertion
|
When we asked about the long-term treatment of BD, after having excluded from the analyses the 3 SGAs with a European indication for maintenance BD treatment (aripiprazole, olanzapine, and quetiapine), asenapine was considered either “highly appropriate” or “appropriate” by 44.6% of the respondents, while other off-label SGAs (clozapine, paliperidone, risperidone, ziprasidone) were mostly considered inappro- priate for maintenance bipolar treatment
|
|
||||
|
Assertion
|
|
|||||
|
Assertion
|
|
|||||
|
Assertion
|
|
|||||
|
Assertion
|
|
|||||
|
Assertion
|
|
|||||
|
Assertion
|
|
|||||
|
Assertion
|
|
|||||
|
Assertion
|
|